Summary
ACLX Chart
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Here is how Arcellx, Inc. (ACLX) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Bamco Inc. NY Has $45.17 Million Stake in Arcellx, Inc. $ACLX
Bamco Inc. NY lifted its holdings in Arcellx, Inc. (NASDAQ: ACLX) by 6.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 550,236 shares of the company's stock after acquiring an additional 32,227 shares during the quarter. Bamco Inc. NY owned
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
Gilead plans a $7.8B Arcellx acquisition as cell therapy sales decline, seeking full control of anito-cel to strengthen its oncology pipeline.
Arcellx, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 40 | $2,624 | $2,624 | - | - |
| ADD Andrew D. Dickinson GILEAD SCIENCES Inc. | 6.72M | $515.42M | $515.42M | - | - |
 George Soros Soros Fund Management LLC | 200,000 | $22.96M | $22.96M | - | - |
 Point72 Asset Management LP Point72 Asset Management LP | 9,843 | $1.13M | $1.13M | - | - |
 David Kim Paradigm Biocapital Advisors LP | 5.77M | $281,840.56 | $178,879.02 | -$102,961.54 | -36.53% |
Arcellx, Inc. (ACLX) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Arcellx, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Rami Elghandour CEO | NASDAQ (NGS) Exchange | 03940C100 CUSIP |
| US Country | 163 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Arcellx, Inc., initially known as Encarta Therapeutics, Inc., underwent a name change in January 2016 and was established in 2014. Its headquarters is situated in Redwood City, California, in the United States. This innovative biotechnology company, along with its subsidiary, is at the forefront of developing advanced immunotherapies designed for the treatment of cancer and other incurable diseases. Arcellx's strategic partnership with Kite Pharma, Inc. underscores its commitment to the advancement of novel therapies, specifically highlighting their joint efforts in co-developing and co-commercializing their leading ddCAR product candidate, anitocabtagene autoleucel.
Products and Services
- Anitocabtagene Autoleucel (Lead ddCAR Product Candidate)
This cutting-edge therapy is currently in phase 2 clinical trials and represents Arcellx's flagship endeavor in addressing relapsed or refractory multiple myeloma (rrMM). Through its strategic alliance with Kite Pharma, Inc., this therapy embodies the company's concentrated efforts in pioneering cancer treatment solutions.
- ACLX-001
Targeting BCMA (B-cell maturation antigen) for the treatment of rrMM, ACLX-001 has entered Phase 1 clinical trials. This product candidate signifies Arcellx's dedication to diversifying its portfolio in therapies against multiple myeloma, underscoring a focused approach towards addressing relapsed or refractory cases.
- ACLX-002
This candidate is making strides in Phase 1 clinical trials targeting CD123, aimed at treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ACLX-002 exemplifies Arcellx's venture into hematological malignancies beyond multiple myeloma, expanding its therapeutic reach.
- Preclinical Product: ACLX-003
Still in the preclinical stage, ACLX-003 is being developed for the treatment of AML and MDS, highlighting Arcellx's ongoing research and development efforts in combating a broader spectrum of hematologic conditions.
- Focus on Solid Tumor Programs
In addition to its commitment to hematologic malignancies, Arcellx is also channeling efforts into developing product candidates aimed at treating solid tumors. This initiative signifies the company's broader ambition to address a wide array of cancer types, thereby broadening its impact in the oncology sphere.
